Immune Responses in Post Kala-azar Dermal Leishmaniasis
- PMID: 33487699
- PMCID: PMC7810083
- DOI: 10.4103/ijd.IJD_258_20
Immune Responses in Post Kala-azar Dermal Leishmaniasis
Abstract
Kala-azar, commonly known as visceral leishmaniasis (VL), is a neglected tropical disease that has been targeted in South Asia for elimination by 2020. Presently, the Kala-azar Elimination Programme is aimed at identifying new low-endemic foci by active case detection, consolidating vector control measures, and decreasing potential reservoirs, of which Post Kala-azar Dermal Leishmaniasis (PKDL) is considered as the most important. PKDL is a skin condition that occurs after apparently successful treatment of VL and is characterized by hypopigmented patches (macular) or a mixture of papules, nodules, and/or macules (polymorphic). To achieve this goal of elimination, it is important to delineate the pathophysiology so that informed decisions can be made regarding the most appropriate and cost-effective approach. We reviewed the literature with regard to PKDL in Asia and Africa and interpreted the findings in establishing a potential correlation between the immune responses and pathophysiology. The overall histopathology indicated the presence of a dense, inflammatory cellular infiltrate, characterized by increased expression of alternatively activated CD68+ macrophages, CD8+ T cells showing features of exhaustion, CD20+ B cells, along with decreased CD1a+ dendritic cells. Accordingly, this review is an update on the overall immunopathology of PKDL, so as to provide a better understanding of host-parasite interactions and the immune responses generated which could translate into availability of markers that can be harnessed for assessment of disease progression and improvement of existing treatment modalities.
Keywords: Immune response; kala-azar; post kala-azar dermal leishmaniasis; visceral leishmaniasis.
Copyright: © 2020 Indian Journal of Dermatology.
Conflict of interest statement
There are no conflicts of interest.
Figures
References
-
- Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392:951–70. - PubMed
-
- Zijlstra EE, Musa AM, Khalil EAG, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3:87–98. - PubMed
-
- Ganguly S, Das NK, Barbhuiya JN, Chatterjee M. Post-kala-azar dermal leishmaniasis-an overview. Int J Dermatol. 2010;49:921–31. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials